Processa Pharma FY2022 net loss $27.4M; cash raised to $12.9M; NGC-Cap Phase 2B to start H2 2023

Processa Pharmaceuticals, Inc.

2024-Q1 EPS reported -$3.53

Net loss for year ended Dec 31, 2022 was $27.4M ($1.70 per share) vs $11.4M ($0.75) in 2021, including $7.3M non-cash intangible impairment.
Cash of $6.5M at year-end; subsequently raised $6.4M net from registered direct offering, total $12.9M expected to fund operations into Q3 2024.
R&D expenses $11.5M (2022) vs $6.9M (2021); G&A $8.8M vs $4.7M, driven by stock-based comp and trial costs.
FDA meeting in mid-April to discuss Next Generation Capecitabine Phase 2B trial; initiation expected H2 2023 in colorectal cancer.
Dose escalations for NGC-Cap continue with no adverse events; Phase 2A gastroparesis trial completed, out-licensing for non-oncology assets.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Processa Pharmaceuticals, Inc. reported year ended December 31, 2022 results: net income $27.4 million, or $1.70 per share, EPS $1.70 per share.

Period: year ended December 31, 2022
Net income: $27.4 million, or $1.70 per share
EPS: $1.70 per share
Result: reported results

Exact text from the filing

Our net loss for the year ended December 31, 2022 was $27.4 million, or $1.70 per share, compared to a net loss of $11.4 million, or $0.75 per share for the same period of 2021.

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

Processa Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-23-009935

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.